Intech Biopharm Corporation (TPEX:6461)
Taiwan
· Delayed Price · Currency is TWD 18.00
-0.05 (-0.28%)
Apr 29, 2026, 1:17 PM CST
Intech Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 107.53 | 39.78 | 25.85 | 23.65 | 38.9 | Upgrade
|
| Revenue Growth (YoY) | 170.31% | 53.90% | 9.30% | -39.21% | 84.30% | Upgrade
|
| Cost of Revenue | 218.47 | 197.4 | 189.84 | 170.91 | 158.27 | Upgrade
|
| Gross Profit | -110.94 | -157.63 | -164 | -147.26 | -119.37 | Upgrade
|
| Selling, General & Admin | 63.62 | 55.44 | 51.99 | 52.14 | 47.98 | Upgrade
|
| Research & Development | 189.94 | 143.06 | 104.49 | 118.68 | 126.63 | Upgrade
|
| Operating Expenses | 253.56 | 198.5 | 156.47 | 170.82 | 174.61 | Upgrade
|
| Operating Income | -364.5 | -356.13 | -320.47 | -318.08 | -293.98 | Upgrade
|
| Interest Expense | -33.52 | -34.16 | -33.59 | -23.04 | -19.54 | Upgrade
|
| Interest & Investment Income | 3.94 | 5.73 | 4.42 | 1.93 | 0.85 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.46 | 0.03 | 0.04 | 0.18 | -0.08 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.31 | 16.31 | 11.61 | 11.14 | 11 | Upgrade
|
| Pretax Income | -382.23 | -368.21 | -337.99 | -327.88 | -301.76 | Upgrade
|
| Income Tax Expense | 6.8 | - | - | - | - | Upgrade
|
| Net Income | -389.03 | -368.21 | -337.99 | -327.88 | -301.76 | Upgrade
|
| Net Income to Common | -389.03 | -368.21 | -337.99 | -327.88 | -301.76 | Upgrade
|
| Shares Outstanding (Basic) | 152 | 137 | 120 | 116 | 102 | Upgrade
|
| Shares Outstanding (Diluted) | 152 | 137 | 120 | 116 | 102 | Upgrade
|
| Shares Change (YoY) | 10.47% | 13.97% | 3.73% | 14.15% | 1.47% | Upgrade
|
| EPS (Basic) | -2.57 | -2.68 | -2.81 | -2.82 | -2.97 | Upgrade
|
| EPS (Diluted) | -2.57 | -2.68 | -2.81 | -2.82 | -2.97 | Upgrade
|
| Free Cash Flow | -423.02 | -312.84 | -234.17 | -201.13 | -221.91 | Upgrade
|
| Free Cash Flow Per Share | -2.79 | -2.28 | -1.94 | -1.73 | -2.18 | Upgrade
|
| Gross Margin | -103.18% | - | - | - | - | Upgrade
|
| Operating Margin | -338.99% | -895.26% | -1239.87% | -1345.12% | -755.76% | Upgrade
|
| Profit Margin | -361.80% | -925.63% | -1307.64% | -1386.55% | -775.74% | Upgrade
|
| Free Cash Flow Margin | -393.41% | -786.44% | -905.98% | -850.56% | -570.48% | Upgrade
|
| EBITDA | -274.52 | -269.8 | -235.74 | -232.8 | -208.82 | Upgrade
|
| EBITDA Margin | -255.31% | - | - | - | - | Upgrade
|
| D&A For EBITDA | 89.98 | 86.33 | 84.73 | 85.28 | 85.16 | Upgrade
|
| EBIT | -364.5 | -356.13 | -320.47 | -318.08 | -293.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.